Iodide transporter NIS regulates cancer cell motility and invasiveness by interacting with the rho guanine nucleotide exchange factor LARG

Cancer Research

Volumn 72, Issue 21, 2012, Pages 5505-5515

  Lacoste, Claire ^a,b   Hervé, Julie ^a,b,g   Nader, Myriam Bou ^a,b   Santos, Alexandre Dos ^a,b   Moniaux, Nicolas ^a,b   Valogne, Yannick ^a,b   Montjean, Rodrick ^c,d   Dorseuil, Olivier ^c,d   Samuel, Didier ^a,b   Cassio, Doris ^b,e   Portulano, Carla ^f   Carrasco, Nancy ^f   Bréchot, Christian ^a,b   Faivre, Jamila ^a,b  

^a HÔPITAL PAUL BROUSSE   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSTITUT COCHIN   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e INSERM   (France)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g LUNAM UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GUANINE NUCLEOTIDE EXCHANGE FACTOR; PERTECHNETIC ACID TC 99M; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; SODIUM IODIDE SYMPORTER;

ARTICLE; CANCER CELL; CARCINOMA; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL ORGANELLE; CELL SURFACE; CONTROLLED STUDY; DRUG UPTAKE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR SIGNALING; ION TRANSPORT; LIVER METASTASIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; TARGET CELL; TUMOR GROWTH; UPREGULATION;

CELL LINE, TUMOR; CELL MOVEMENT; FLUORESCENT ANTIBODY TECHNIQUE; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; NEOPLASM INVASIVENESS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SYMPORTERS; TRANSDUCTION, GENETIC; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 84868258397     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-0516     Document Type: Article

References (50)

1. Ganapathy V, Thangaraju M, Prasad PD. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther 2009;121:29M40.
2. Weihua Z, Tsan R, Huang WC, Wu Q, Chiu CH, Fidler IJ, et al. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 2008;13:385-93.
3. Li H, Myeroff L, Smiraglia D, Romero MF, Pretlow TP, Kasturi L, et al. SLC5A8, asodiumtransporter, isatumorsuppressorgenesilencedby methylation in human colon aberrant crypt foci and cancers. Proc Natl Acad Sci U S A 2003;100:8412-7.
4. Thangaraju M, Gopal E, Martin PM, Ananth S, Smith SB, Prasad PD, et al. SLC5A8 triggers tumor cell apoptosis through pyruvate-depen-dent inhibition ofhistonedeacetylases. Cancer Res2006;66:11560-4.
5. Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodidetransporter. Nature 1996;379:458-60.
6. Smanik PA, Liu Q, Furminger TL, Ryu K, Xing S, Mazzaferri EL, et al. Cloning of the human sodium lodide symporter. Biochem Biophys Res Commun 1996;226:339-45.
7. Tazebay UH, Wapnir IL, Levy O, Dohan O, Zuckier LS, Zhao QH, et al. The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nat Med 2000;6:871-8.
8. Rillema JA, Yu TX, Jhiang SM. Effect of prolactin on sodium iodide symporter expression in mouse mammary gland explants. Am J Physiol Endocrinol Metab 2000;279:E769-72.
9. Postiglione MP, Parlato R, Rodriguez-Mallon A, Rosica A, Mithbaokar P, Maresca M, et al. Role ofthethyroid-stimulating hormone receptor signaling in developmentand differentiation ofthethyroid gland. Proc Natl Acad Sci U S A 2002;99:15462-7.
10. Di Cosmo C, Fanelli G, Tonacchera M, Ferrarini E, Dimida A, Agretti P, et al. The sodium-iodide symporter expression in placental tissue at different gestational age: an immunohistochemical study. Clin Endo-crinol (Oxf) 2006;65:544-8.
11. Upadhyay G, Singh R, Agarwal G, Mishra SK, Pal L, Pradhan PK, et al. Functional expression of sodium iodide symporter (NIS) in human breast cancer tissue. Breast Cancer Res Treat 2003;77: 157-65.
12. +/Γ symporter mediates iodide uptake in breast cancer metastases and can beselectivelydown-regulated inthethyroid. Clin Cancer Res 2004;10:4294-302.
13. Liu B, Herve J, Bioulac-Sage P, Valogne Y, Roux J, Yilmaz F, et al. Sodium iodide symporter is expressed at the preneoplastic stages of liver carcinogenesis and in human cholangiocarcinoma. Gastroenter-ology 2007;132:1495-503.
14. Renier C, Vogel H, Offor O, Yao C, Wapnir I. Breast cancer brain metastasesexpressthesodium iodidesymporter. J Neurooncol 2009; 96:331-6.
15. Liu XH, Chen GG, Vlantis AC, van Hasselt CA. Iodine mediated mechanisms and thyroid carcinoma. Crit Rev Clin Lab Sci 2009;46: 302-18.
16. Kogai T, Schultz JJ, Johnson LS, Huang M, Brent GA. Retinoic acid induces sodium/iodide symporter gene expression and radioiodide uptake in the MCF-7 breast cancer cell line. Proc Natl Acad Sci U S A 2000;97:8519-24.
17. Ohashi E, Kogai T, Kagechika H, Brent GA.Activation of the PI3kinase pathway by retinoicacid mediatessodium/iodidesymporterinduction and iodide transport in MCF-7 breast cancer cells. Cancer Res 2009;69:3443-50.
18. Dentice M, Luongo C, Elefante A, Romino R, Ambrosio R, Vitale M, et al. Transcription factor Nkx-2.5 induces sodium/iodide symporter gene expression and participates in retinoic acid- and lactation-induced transcription in mammary cells. Mol Cell Biol 2004;24: 7863-77.
19. Formstecher E, Aresta S, Collura V, Hamburger A, Meil A, Trehin A, et al. Protein interaction mapping: a Drosophila case study. Genome Res 2005;15:376-84.
20. Huh N, Utakoji T. Production of HBs-antigen by two new human hepatoma cell lines and its enhancement by dexamethasone. Gann 1981;72:178-9.
21. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 1982;42:3858-63.
22. Shimizu Y, Demetris AJ, Gollin SM, Storto PD, Bedford HM, Altarac S, et al. Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells. Int J Cancer 1992;52: 252-60.
23. Fukuhara S, Murga C, Zohar M, Igishi T, Gutkind JS. A novel PDZ domain containing guanine nucleotide exchange factor links hetero-trimeric G proteins to Rho. J Biol Chem 1999;274:5868-79.
24. Fukuhara S, Chikumi H, Gutkind JS. Leukemia-associated Rho gua-nine nucleotide exchangefactor (LARG) links heterotrimeric G proteins of the G(12) family to Rho. FEBS Lett 2000;485:183-8.
25. Goulimari P, Knieling H, Engel U, Grosse R. LARG and m Dia1 link Galpha12/13 to cell polarity and microtubule dynamics. Mol Biol Cel 2008;19:30-40.
26. Hodges A, Sharrocks K, Edelmann M, Baban D, Moris A, Schwartz O, et al. Activation of the lectin DC-SIGN induces an immature dendritic cell phenotype triggering Rho-GTPase activity required for HIV-1 replication. Nat Immunol 2007;8:569-77.
27. Takaya H, Andoh A, Shimada M, Hata K, Fujiyama Y, Bamba T. The expression of chemokine genes correlates with nuclearfactor-kappa B activation in human pancreatic cancercell lines. Pancreas 2000;21:
28. Faivre J, Clerc J, Gerolami R, Herve J, Longuet M, Liu B, et al. Long-term radioiodine retention and regression of liver cancer after sodium iodide symporter gene transfer in wistar rats. Cancer Res 2004;64: 8045-51.
29. Herve J, Sa Cunha A, Liu B, Valogne Y, Longuet M, Boisgard R, et al. Internal radiotherapy of liver cancer with rat hepatocarcinoma-intes-tine- pancreasgeneasalivertumor-specificpromoter. Hum Gene Ther 2008;19:915-26.
30. Dohan O, De la Vieja A, Paroder V, Riedel C, Artani M, Reed M, et al. The sodium/iodidesymporter (NIS): characterization, regulation, and med-ical significance. Endocr Rev 2003;24:48-77.
31. Reuther GW, Lambert QT, Booden MA, Wennerberg K, Becknell B, Marcucci G, et al. Leukemia-associated Rho guanine nucleotide exchange factor, a Dbl family protein found mutated in leukemia, causes transformation by activation of Rho A. J Biol Chem 2001; 276:27145-51.
32. Booden MA, Siderovski DP, Der CJ. Leukemia-associated Rho gua-nine nucleotide exchange factor promotes G alpha q-coupled activa-tion of Rho A. Mol Cell Biol 2002;22:4053-61.
33. Taya S, Inagaki N, Sengiku H, Makino H, Iwamatsu A, Urakawa I, et al. Direct interaction of insulin-like growth factor-1 receptorwith leuke-mia-associated Rho GEF. J Cell Biol 2001;155:809-20.
34. Aurandt J, Vikis HG, Gutkind JS, Ahn N, Guan KL. The semaphorin receptor plexin-B1 signals through a direct interaction with the Rho-specific nucleotide exchange factor, LARG. Proc Natl Acad Sci U S A 2002;99:12085-90.
35. Swiercz JM, Kuner R, Behrens J, Offermanns S. Plexin-B1 directly interacts with PDZ-Rho GEF/LARG to regulate Rho A and growth cone morphology. Neuron 2002;35:51-63.
36. Hata K, Kaibuchi K, Inagaki S, Yamashita T. Unc5B associates with LARG to mediate the action of repulsive guidance molecule. J Cell Biol 2009;184:737-50.
37. 2+ signaling, and cytoskeleton modifica-tion in head and neck squamous cell carcinoma cells. J Biol Chem 2006;281:14026-40.
38. Kitzing TM, Sahadevan AS, Brandt DT, Knieling H, Hannemann S, Fackler OT, et al. Positive feedback between Dia1, LARG, and Rho A regulates cell morphologyand invasion.Genes Dev2007;21:1478-83.
39. Pfreimer M, Vatter P, Langer T, Wieland T, Gierschik P, Moepps B. LARG links histamine-H1-receptor-activated G(q) to Rho-GTPase-dependent signaling pathways. Cell Signal 2012;24:652-63.
40. Okuhira K, Fitzgerald ML, Tamehiro N, Ohoka N, Suzuki K, Sawada J, et al. Bindingof PDZ-Rho GEFto ATP-bindingcassettetransporter A1 (ABCA1) induces cholesterol effluxthrough Rho A activation and pre-vention oftransporterdegradation. J Biol Chem 2010;285:16369-77.
41. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, et al. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 2008;93: 4331-41.
42. Puppin C, D'Aurizio F, D'Elia AV, Cesaratto L, Tell G, Russo D, et al. Effects of histone acetylation on sodium iodide symporter promoter and expression of thyroid-specifictranscription factors. Endocrinolo-gy 2005;146:3967-74.
43. Webb DJ, Horwitz AF. New dimensions in cell migration. Nat Cell Biol 2003;5:690-2.
44. Paroder V, Spencer SR, Paroder M, Arango D, Schwartz S Jr, Mar-iadason JM, et al. Na(+)/monocarboxylate transport (SMCT) protein expression correlates with survival in colon cancer: molecular char-acterization of SMCT. Proc Natl Acad Sci U S A 2006;103:7270-5.
45. +/Γ symporter. Mol Endocrinol 2005;19:2847-58.
46. Smith VE, Read ML, Turnell AS, Watkins RJ, Watkinson JC, Lewy GD, et al. A novel mechanism of sodium iodide symporter repression in differentiated thyroid cancer. J Cell Sci 2009;122:3393-402.
47. Sahai E. Illuminating the metastatic process. Nat Rev Cancer 2007;7: 737-49.
48. Costamagna E, Garcia B, Santisteban P. The functional interaction between the paired domain transcription factor Pax8 and Smad3 is involved in transforming growth factor-beta repression of the sodium/ iodide symporter gene. J Biol Chem 2004;279:3439-46.
49. Riesco-Eizaguirre G, Rodriguez I, De la Vieja A, Costamagna E, Carrasco N, Nistal M, et al. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res 2009;69:8317-25.
50. Knostman KA, Mc Cubrey JA, Morrison CD, Zhang Z, Capen CC, Jhiang SM. PI3K activation is associated with intracellular sodium/ iodide symporter protein expression in breast cancer. BMC Cancer 2007;7:137.